Navigation Links
Rosetta Genomics Establishes Medical Advisory Board
Date:2/4/2008

World Renowned Clinicians in the Fields of Cancer and Women's Health to

Assist Company in Designing its MicroRNA Development Program to Best

Address Current Medical Needs

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, February 4 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today the establishment of its Medical Advisory Board. Rosetta Genomics has assembled world-leading clinicians in the fields of oncology and women's health, to advise the company on its microRNA-based program to develop laboratory tests to best address the issues facing oncologists and pathologists today. Some laboratory tests comprising Rosetta Genomics technology are expected to be launched in 2008.

"There is great unmet medical need for improved diagnostic and therapeutic tools within the medical community," noted Prof. Moshe Hod, Director of the Division of Maternal Fetal Medicine in the Helen Schneider Hospital for Women at Rabin Medical Center and Chairman of the Medical Advisory Board. "Rosetta Genomics has been a pioneering force in the microRNA field, and its diagnostic and therapeutic development programs may offer clinicians next-generation tools to assist patients. It is the Medical Advisory Board's responsibility to advise the company to help focus its efforts on the most significant medical needs, where microRNAs can have the most impact."

"The diagnostics field has been lagging behind therapeutics in development, despite the tremendous importance of having objective and accurate diagnostic tools to identify patients' conditions and manage their therapy," noted Harvey I. Pass, M.D. Professor of Cardiothoracic Surgery and Surgery, Director of Surgical Research, and Division Chief for Thoracic Surgery and Thoracic Oncology for the NYU School of Medicine and Vice Chairman of the Medical Advisory Board. "MicroRNAs have the potential to be highly specific and sensitive biomarkers, offering clinicians th
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ANGELES , Aug. 4, 2015   California ... the recent acquisition of LifeLine Cryogenics, an east coast ... New York tristate area. LifeLine ... and all prepaid contracts will be honored. ... cryogenics services, offering storage of sperm, eggs, embryos, and ...
(Date:8/3/2015)... 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... the second quarter 2015 on Monday, August 10, 2015 ... Torley , president and chief executive officer, will lead ... release financial results for the second quarter 2015. ... "Investors" section of Halozyme,s corporate website and a recording ...
(Date:8/3/2015)... , August 3, 2015 ... Portland Hospital waved the shortfall of ... could stand normally for the first time. ... (Photo: http://photos.prnewswire.com/prnh/20150803/254229 ) The Selective ... legs allowing him to carry out his wish to ...
(Date:8/3/2015)... London, UK (PRWEB) , ... August 03, 2015 ... ... largest consumer of benzene. Benzene is processed to get such derivatives as ethylbenzene, ... Ethylbenzene derivatives are principally used within the automotive industry for the production of ...
Breaking Biology Technology:FamilyCord Announces Acquisition of LifeLine Cryogenics 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3
... Pharmaceutical Inc.,("Dragon" or the "Company" TSX: DDD; ... company, today announced it has retained,cQuest, a ... facilitate,and execute its investor and media relations ... capitalizations of less than $200,million to achieve ...
... March 17 STAAR Surgical,Company (Nasdaq: STAA ... invasive ophthalmic products, today announced that the Afinity,Collamer(R) ... been,designated as a New Technology Intraocular Lens (NTIOL) ... To receive NTIOL recognition an IOL,must first be ...
... &,Associates (LE&A) today announced it has added the West ... of health care clients., Based in Grand Rapids, ... state,s largest investor relations firm. The firm,will provide public ... life science industry is growing at a rapid rate ...
Cached Biology Technology:Dragon retains leading investor relations firm 2Dragon retains leading investor relations firm 3STAAR Surgical's Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services 2STAAR Surgical's Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services 3STAAR Surgical's Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services 4Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative 2
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... power a large electric grid 99.9 percent of the ... expenses, according to new research by the University of ... combination of wind power, solar power and storage in ... demands while keeping costs low, the scientists found. ...
... insight into evolutional biology by tracing directionality in gene migration ... Masucci from the Centre for Advanced Spatial Analysis, at University ... genes that a marine plant underwent during its evolution. They ... populations of a marine plant went westward from the Mediterranean ...
... Radiation and chemotherapy can pack a powerful punch against ... often left with bad news: Their treatments have rendered ... that it is possible to remove testicular stem cells ... later, after cancer treatments, transplant these cells where they ...
Cached Biology News:Renewables and storage could power grid 99.9 percent of the time 2Renewables and storage could power grid 99.9 percent of the time 3Tracking gene flow in marine plant evolution 2Stem cell research provides hope for infertile cancer survivors 2
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
... Synthetic peptide derived from the C-terminal ... Specificity: Specific for the junctophilin-2 protein. ... skeletal muscle homogenates frozen mouse skeletal ... Immunohistochemistry(froz) ImmunofluorescenceStorage: Store at -20C for ...
Laminin gamma-2 (G-16)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Biology Products: